Status:
COMPLETED
A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.
Lead Sponsor:
Pfizer
Conditions:
Fibromyalgia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The study is designed to assess if esreboxetine can improve the cognitive function of patients with fibromyalgia. Cognitive function is defined as the ability to concentrate, remember things and make ...
Eligibility Criteria
Inclusion
- Subjects who have a recognised diagnosis of fibromyalgia, with defined minimum pain criteria. Control subjects must not have a fibromyalgia diagnosis or symptoms and must match fibromyalgia subjects for age, length of education and gender
Exclusion
- Other confounding pain, cognitive disease or impairment, disease that could put the subject at risk or subjects who are on prohibited medications that cannot be washed out.
- Any subjects with a diagnosis of certain psychiatric disorders in particular major depression or suicidal risk. Matched control subjects have similar exclusions.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT00752505
Start Date
August 1 2008
End Date
June 1 2009
Last Update
December 4 2018
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Destin, Florida, United States, 32541
2
Pfizer Investigational Site
Fort Walton Beach, Florida, United States, 32547
3
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109
4
Pfizer Investigational Site
Bingham Farms, Michigan, United States, 48025